Moreover, this molecular subtype is more frequently diagnosed in younger patients (median 57 vs. 64 y.o., METABRIC9) and at advanced metastatic stage III/IV, in 54% of cases compared with 36% of hormone receptor-positive/HER2-negative breast cancer and 41% of triple-negative breast cancer, another aggressive subtype5. Here, ERBB2 is linked to breast cancer.